Commentary
Evan A. Feigenbaum
{
"authors": [
"Evan A. Feigenbaum"
],
"type": "legacyinthemedia",
"centerAffiliationAll": "dc",
"centers": [
"Carnegie Endowment for International Peace"
],
"collections": [],
"englishNewsletterAll": "asia",
"nonEnglishNewsletterAll": "",
"primaryCenter": "Carnegie Endowment for International Peace",
"programAffiliation": "AP",
"programs": [
"Asia"
],
"projects": [],
"regions": [
"North America",
"United States",
"South Asia",
"East Asia",
"Central Asia"
],
"topics": []
}
REQUIRED IMAGE
In The Media
Evolving U.S. Policy Toward Central and South Asia: Lessons from the Bush Administration
Before China had its “Belt and Road,” the United States actively shaped the future of Eurasia, proposing connectivity initiatives in Central Asia and dramatically reshaping its relationship with India.
Published on Nov 30, 2020
About the Author
Evan A. Feigenbaum
Vice President for Studies
Evan A. Feigenbaum is vice president for studies at the Carnegie Endowment for International Peace, where he oversees work at its offices in Washington, New Delhi, and Singapore on a dynamic region encompassing both East Asia and South Asia. He served twice as Deputy Assistant Secretary of State and advised two Secretaries of State and a former Treasury Secretary on Asia.
- In Its Iran War Debate, Washington Has Lost the Plot in Asia
- Beijing Doesn’t Think Like Washington—and the Iran Conflict Shows WhyCommentary
Evan A. Feigenbaum
Recent Work
Carnegie does not take institutional positions on public policy issues; the views represented herein are those of the author(s) and do not necessarily reflect the views of Carnegie, its staff, or its trustees.
More Work from Carnegie Endowment for International Peace
- The Two Logics Driving Japan’s Security PolicyArticle
Japan’s revision of its three strategic documents reflects an intention to keep the United States engaged in the region while Japan fills any vacuums of U.S. power to preserve the Indo-Pacific order.
Ryo Sahashi
- Caught in the Middle: Chinese Biotech Firms’ Divergent Responses to U.S. SanctionsCommentary
Chinese biotech companies have been on the receiving end of U.S. economic coercion. Yet their responses have differed significantly because firm and state interests are not uniformly aligned. For Washington, treating all Chinese tech firms the same, irrespective of their actual interests, risks pushing them farther into Beijing’s corner.
Xue Gong
- Inside the Global Race to Erode a Battery Manufacturing MonopolyCommentary
Over the past decade, China has moved from marginal player to major producer of all things batteries. The United States, Europe, and others are aiming to balance the market.
Milo McBride
- A Geothermal and Nuclear Strategy for the U.S. International Development Finance CorporationPaper
The DFC should focus on advanced, low-carbon energy sources, prioritizing areas where the United States has comparative advantages.
Noah Gordon, Liana Schmitter-Emerson
- Why Korea’s President Skipped Washington for Silicon Valley and BrasíliaCommentary
Lee’s tour shows how Seoul is reorganizing its diplomacy away from Pyongyang and toward industrial networks and the geography of the compute economy.
Darcie Draudt-Véjares
